Giao dịch Emergent BioSolutions Inc. - EBS CFD

Điều kiện giao dịch

• Loại: CFD
• Chênh lệch: 0.21
• Điều chỉnh phí tài trợ qua đêm cho vị thế mua: -0.02154%
• Điều chỉnh phí tài trợ qua đêm cho vị thế bán: -0.00068%
• Thời gian điều chỉnh phí tài trợ qua đêm: 22:00 (UTC)
• Tiền tệ: USD
• Số lượng giao dịch tối thiểu: 1
• Biên lợi nhuận: 5.00%
• Sàn giao dịch chứng khoán: United States of America
• Phí hoa hồng giao dịch: 0%
• Bảo đảm dừng phí bảo hiểm: 1%

Số liệu thống kê chính

• Trước đó Đóng: 12
• Mở: 11.85
• Thay đổi 1 năm: 9.72%
• Phạm vi trong ngày: 11.85 - 12.36

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. The company offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. It also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, the company offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4/7. Further, it offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, the company offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies/non-governmental organizations. Emergent BioSolutions Inc. has a development and manufacturing agreement with Novavax Inc. for coronavirus disease vaccine candidate. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.